Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16587944 | 0.85 | KAT2B (0.36) | KAT2BBAZ2BPIK3CDACACBL3MBTL1 | |
| SCHEMBL305547 | 0.83 | EPHX1 (0.39) | HPGDTSHRNPSR1 | |
| SCHEMBL9669443 | 0.83 | EPHX1 (0.35) | ACACB | |
| SCHEMBL13319823 | 0.82 | PIK3CD (0.36) | KAT2BBAZ2BPIK3CDACACBL3MBTL1 | |
| SCHEMBL20123344 | 0.82 | KAT2B (0.38) | KAT2BBAZ2BPIK3CDACACBL3MBTL1 | |
| SCHEMBL6580932 | 0.82 | KAT2B (0.35) | KAT2BBAZ2BPIK3CDACACBL3MBTL1 | |
| SCHEMBL16622507 | 0.81 | EPHX1 (0.42) | TSHR | |
| SCHEMBL305826 | 0.81 | EPHX1 (0.42) | TSHR | |
| SCHEMBL5987438 | 0.79 | PIK3CD (0.35) | KAT2BBAZ2BPIK3CDACACBHRH3 | |
| SCHEMBL5985348 | 0.79 | PIK3CD (0.35) | KAT2BBAZ2BPIK3CDACACBHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248941-A1 | Benzimidazone compound, process for producing the same, and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
| EP-1437352-A1 | BENZIMIDAZOLE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248941-A1 | Benzimidazone compound, process for producing the same, and use thereof | SI, MLNR, FABP2 | KAT2B 1250/4885BAZ2B 468/4885PIK3CD 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.